CEO Geoffrey Allan Will Discuss Company's IPLEX(TM) Program in Myotonic
RICHMOND, Va., July 25 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM) a developer of follow-on biologics and biopharmaceuticals, today announced that Geoffrey Allan, Ph.D., CEO of Insmed, will present at IBC's 13th Annual Drug Discovery and Development of Innovative Therapeutics on Thursday, August 7th, 2008 at 9:25 AM ET.
Dr. Allan will be participating in the Orphan Diseases track of the conference and his presentation will be entitled, "Myotonic Muscular Dystrophy - A Major Unmet Medical Need." He will present Insmed's progress with its Phase II trial for IPLEX(TM) in Myotonic Muscular Dystrophy. The trial, which has seen strong patient and physician interest, is now fully enrolled. It is a six month, randomized, double-blind, placebo-controlled trial being conducted at 13 research centers across the U.S.
The conference will be held from August 4th to August 7th, 2008, at the World Trade Center Boston and the Seaport Hotel in Boston, MA.
Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.
This release contains forward-looking statements which are made
pursuant to provisions of Section 21E of the Securities Exchange Act of
1934. Investors are cautioned that such statements in this release,
including statements relating to planned clinical study design, regulatory
and business strategies, strategic alternatives, plans and objectives of
management and growth opportunities for existing or proposed products,
constitute forward-looking statements which involve risks and uncertainties
that could cause actual results to differ materially from those anticipated
by the forward-looking statements. The risks and uncertainties include,
without limitation, risks that strategic alternatives may never be
consummated, product candidates may fail in the clinic or may not be
successfully marketed or manufactured, we may lack financial resources to
complete development of product candidates, the FDA may interpret the
results of studies differently than us, competing products may be more
successful, demand for new pharmaceutical products may decrease, the
biopharmaceutical industry may experience negative market trends, our
entrance into the follow-on biologics market may be unsuccessful, our
common stock could be delisted from The NASDAQ Capital Market and other
risks and challenges detailed in the Company's filings with the U.S.
Securities and Exchange Commission, including the Company's Annual Report
on Form 10-K for the year ended December 31, 2007. Readers are cautioned
not to place undue reliance on any forward-looking statements which speak
only as of the date of this release. The Company undertakes no obligation
to publicly release the results of any revisions to these forward-looking
statements that may be made to reflect events or circumstances that occur
after the date of this release or to reflect the occurrence of
Investor Relations Contact:
Brian Ritchie - FD
Corporate Communications Contact:
John Procter - Gibraltar Associates
|SOURCE Insmed Inc.|
Copyright©2008 PR Newswire.
All rights reserved